Percutaneous parathyroid ethanol ablation in patients with multiple endocrine neoplasia type 1.
OBJECTIVE
The objective of our study was to show the efficacy and safety of percutaneous ethanol ablation in managing recurrent primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1 (MEN1) after subtotal parathyroidectomy.


CONCLUSIONS
Ethanol ablation is a viable alternative to reoperation for the management of recurrent primary hyperparathyroidism in patients with MEN1.
Veldman
Mark W
MW
Department of Radiology, Mayo Clinic, 200 1st St., SW, Rochester, MN 55902, USA.
Reading
Carl C
CC
Farrell
Michael A
MA
Mullan
Brian P
BP
Wermers
Robert A
RA
Grant
Clive S
CS
Thompson
Geoff B
GB
D000328:Adult; D000368:Aged; D000431:Ethanol / Q000008:administration & dosage*; D006801:Humans; D006961:Hyperparathyroidism / Q000628:therapy*; D007279:Injections, Subcutaneous; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010282:Parathyroid Neoplasms / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
D000431:Ethanol